X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
Canada
0
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
1. Abactrim
2. Bactifor
3. Bactrim
4. Biseptol
5. Biseptol 480
6. Biseptol-480
7. Biseptol480
8. Centran
9. Centrin
10. Co Trimoxazole
11. Co-trimoxazole
12. Cotrimoxazole
13. Drylin
14. Eslectin
15. Eusaprim
16. Insozalin
17. Kepinol
18. Kepinol Forte
19. Lescot
20. Metomide
21. Oriprim
22. Septra
23. Septrin
24. Sulfamethoxazole Trimethoprim Combination
25. Sulfamethoxazole-trimethoprim Combination
26. Sulprim
27. Sumetrolim
28. Tmp Smx
29. Tmp-smx
30. Trimedin
31. Trimethoprim Sulfamethoxazole
32. Trimethoprim Sulfamethoxazole Combination
33. Trimethoprim, Sulfamethoxazole Drug Combination
34. Trimethoprim-sulfamethoxazole
35. Trimethoprim-sulfamethoxazole Combination
36. Trimethoprimsulfa
37. Trimezole
38. Trimosulfa
1. Sulfamethoxazole & Trimethoprim
2. Sulfamethoxazole + Trimethoprim
3. Co-trimoxazole
4. Trimosulfa
5. Cotrimoxazole
6. Septra
7. 8064-90-2
8. Trimethoprimsulfa
9. Trimforte
10. Sulfamethoxazole-trimethoprim
11. Trimethoprim-sulfamethoxazole
12. Tmp-smx
13. Gantrim
14. Trimethoprim-sulfamethoxazole Combination
15. Trimethoprim/sulfamethoxazole
16. Tmp/smx
17. Trimethoprim And Sulphamethoxazole
18. Sulfamethoxazole Trimethoprim
19. Sulfamethoxazole / Trimethoprim
20. Trimethoprim And Sulfamethoxazole
21. Sulfamethoxazole Mixture With Trimethoprim
22. Nsc618652
23. Abactrim
24. Biseptol
25. Eusaprim
26. Kepinol
27. Oriprim
28. Sulprim
29. Sumetrolim
30. Drylin
31. Kepinol Forte
32. Septra Grape
33. Septra Ds
34. Bactrim Ds
35. Bactrim Pediatric
36. Uroplus Ds
37. Uroplus Ss
38. Sulfatrim Pediatric
39. Sulmeprim Pediatric
40. Aposulfatrim
41. Bactoreduct
42. Cotrimhexal
43. Cotrimoxazol
44. Cotrimstada
45. Duratrimet
46. Jenamoxazol
47. Sulfotrimin
48. Supracombin
49. Trimetoger
50. Trimexazol
51. Agoprim
52. Alfatrim
53. Bacteral
54. Bactilen
55. Bactiver
56. Bactrizol
57. Bactromin
58. Bactropin
59. Berlocid
60. Bibacrim
61. Chemitrim
62. Chemotrim
63. Cotribene
64. Cotriver
65. Dibaprim
66. Eltrianyl
67. Escoprim
68. Esteprim
69. Fectrim
70. Gantaprim
71. Gantaprin
72. Groprim
73. Helveprim
74. Kemoprim
75. Laratrim
76. Linaris
77. Maxtrim
78. Microtrim
79. Mikrosid
80. Momentol
81. Oecotrim
82. Oxaprim
83. Pantoprim
84. Primazole
85. Septrim
86. Septrin
87. Servitrim
88. Sigaprim
89. Sigaprin
90. Sulfotrim
91. Tacumil
92. Teleprim
93. Teleprin
94. Thiocuran
95. Tribakin
96. Trigonyl
97. Trimesulf
98. Uroplus
99. Abacin
100. Bacton
101. Baktar
102. Ciplin
103. Comox
104. Imexim
105. Nopil
106. Omsat
107. Suprim
108. Trifen
109. Bacterial Forte
110. Microtrim Forte
111. Duon
112. Trimetho Comp
113. Cotrimox-wolff
114. Bactrim Forte
115. Co-trimaxazol
116. Cotrim Holsen
117. Cotrimoxazol Al
118. Cotrim-puren
119. Strepto-plus
120. Cotrim-hefa
121. Trimexole-f
122. Baktrisid-ds
123. Co-trim-tablinen
124. Cotrim-radiopharm
125. Sulfa-tyl
126. Sulfameth/tmp
127. Sulfameth/trimeth
128. Cotrim Eu Rho
129. Cotrim_basf
130. Cotrimoxazol-cophar
131. 4-amino-n-(5-methylisoxazol-3-yl)benzenesulfonamide Compound With 5-(3,4,5-trimethoxybenzyl)pyrimidine-2,4-diamine (1:1)
132. Benzenesulfonamide, 4-amino-n-(5-methyl-3-isoxazolyl)-, Mixt. With 5-[(3,4,5-trimethoxyphenyl)methyl]-2,4-pyrimidinediamine
133. Cotrim D.s.
134. Cotrim.l.u.t.
135. Smx-tmp
136. Smx/tmp
137. Sulfamethoxazole-trimeth
138. Sulfamethoxazole / Tmp
139. Smx / Tmp
140. Tmp / Smx
141. Co-trimazole
142. A 033
143. Hsdb 6780
144. Tms 480
145. Benzenesulfonamide, 4-amino-n-(5-methyl-3-isoxazolyl)-, Mixt. With 5-((3,4,5-trimethoxyphenyl)methyl)-2,4-pyrimidinediamine
146. Bactrim (tn)
147. Septra (tn)
148. Nsc 618652
149. Sulfamethoxazole And Trimethoprim Double Strength
150. Sulfamethoxazole And Trimethoprim Single Strength
151. Co-trimoxazole (ban)
152. Epitope Id:141805
153. Tmp & Smx
154. Trimethoprim, Sulfamethoxazole Drug Combination
155. Chembl58061
156. Schembl870329
157. Trimethoprim & Sulfamethoxazole
158. Chebi:3770
159. Dtxsid0032233
160. Nsc-618652
161. Sulfamethoxazole - Trimethoprim Mixture
162. Benzenesulfonamide, 4-a)mino-n-(5-methyl-3-isoxazolyl)-, Mixt. With 5-((3,4,5-trimethoxyphenyl)methyl-2,4-pyrimidinediamine
163. D00285
164. Q898623
165. Benzenesulfonamide, Mixt. With 5-[(3,4,5-trimethoxyphenyl)methyl]-2,4- Pyrimidinediamine
166. 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine
167. 4-amino-n-(5-methylisoxazol-3-yl)benzenesulfonamide; 5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine
168. 50808-41-8
169. Benzenesulfonamide, 4-amino-n-(5-methyl-3-isoxazolyl)- & 5-((3,4,5-trimethoxyphenyl)methyl)-2,4-pyrimidinediamine
170. Pyrimidine, 2,4-diamino-5-(3,4,5-trimethoxybenzyl)- And N'-(5-methyl-3-isoxazolyl)sulfanilamide
171. Sxt
| Molecular Weight | 543.6 g/mol |
|---|---|
| Molecular Formula | C24H29N7O6S |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 13 |
| Rotatable Bond Count | 8 |
| Exact Mass | 543.19000284 g/mol |
| Monoisotopic Mass | 543.19000284 g/mol |
| Topological Polar Surface Area | 212 Ų |
| Heavy Atom Count | 38 |
| Formal Charge | 0 |
| Complexity | 653 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 4 | |
|---|---|
| Drug Name | Septra |
| Active Ingredient | trimethoprim; Sulfamethoxazole |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 400mg; 80mg |
| Market Status | Prescription |
| Company | Monarch Pharms |
| 2 of 4 | |
|---|---|
| Drug Name | Sulfamethoxazole and trimethoprim single strength |
| Active Ingredient | trimethoprim; Sulfamethoxazole |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 400mg; 80mg |
| Market Status | Prescription |
| Company | Teva Pharms |
| 3 of 4 | |
|---|---|
| Drug Name | Sulfamethoxazole and trimethoprim double strength |
| Drug Label | BACTRIM ( |
| Active Ingredient | trimethoprim; Sulfamethoxazole |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 160mg; 800mg |
| Market Status | Prescription |
| Company | Teva |
| 4 of 4 | |
|---|---|
| Drug Name | Sulfamethoxazole and trimethoprim |
| Active Ingredient | trimethoprim; Sulfamethoxazole |
| Dosage Form | Tablet; Suspension; Injectable |
| Route | Injection; Oral |
| Strength | 80mg/ml; 200mg/5ml; 160mg; 40mg/5ml; 400mg; 800mg; 16mg/ml; 80mg |
| Market Status | Prescription |
| Company | Aurobindo Pharma; Teva Pharms Usa; Vista Pharms; Glenmark Generics; Amneal Pharms Ny; Hi Tech Pharma; Mutual Pharm; Vintage |
Anti-Infective Agents; Anti-Infective Agents, Urinary; Antimalarials
National Library of Medicine's Medical Subject Headings online file (MeSH, 1999)
Co-trimoxazole has been used in the treatment of gonorrhea caused by penicillinase-producing Neisseria gonorrhoeae. Although other anti-infective agents are generally recommended by the US Centers for Disease Control and many clinicians for the treatment of urogenital or anorectal infections caused by penicillinase-producing Neisseria gonorrhoeae, co-trimoxazole may be effective for the treatment of pharyngeal infections caused by penicillinase-producing Neisseria gonorrhoeae Although clinical experience is limited, oral co-trimoxazole may also be effective as an alternative to currently recommended regimens for the treatment of acute sexually transmitted epididymitis caused by penicillinase-producing Neisseria gonorrhoeae.
McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 92. Bethesda, MD: American Society of Hospital Pharmacists, Inc., 1992 (Plus Supplements 1992)., p. 463
Trimethoprim/sulfamethoxazole is an alternative to tetracycline in cholera. This combination is recommended in isosporiasis (Isospora belli).
American Medical Association. AMA Drug Evaluations Annual 1991. Chicago, IL: American Medical Association, 1991., p. 1345
Trimethoprim/sulfamethoxazole may be useful in serious infections, including meningitis, osteomyelitis, bacteremia, and endocarditis, caused by susceptible gram-negative bacteria when other antibacterial agents are ineffective or not tolerated. Of particular note, gram-negative bacillary meningitis caused by organisms only moderately susceptible to third generation cephalosporins (eg, Enterobacter cloacae, Serratia marcescens) or resistant to these antibiotics (Acinetobacter, Pseudomonas cepacia) may be candidates for trimethoprim/sulfamethoxazole therapy if the organisms are susceptible. This combination may be an effective alternative to ampicillin (or penicillin G) with or without an aminoglycoside for the treatment of meningitis and bacteremia caused by Listeria monocytogenes. Trimethoprim/sulfamethoxazole may be useful for the treatment of infective endocarditis caused by Coxiella burnetii. In a double-blind, randomized, prospective study, intravenous trimethoprim/sulfamethoxazole (640 mg/3200 mg daily) was shown to be as effective as vancomycin in the treatment of serious methicillin-resistant Staphylococcus aureus infections, including bacteremias, endocarditis, septic arthritis, and osteomyelitis. The details of this study have not been published, however, and some consultants expressed concern about the use of trimethoprim/sulfamethoxazole in deep-seated staphylococcal infections (eg, endocarditis) because this combination may only be bacteriostatic against this organism. Currently, each of these indications is considered investigational.
American Medical Association. AMA Drug Evaluations Annual 1991. Chicago, IL: American Medical Association, 1991., p. 1346
For more Therapeutic Uses (Complete) data for TRIMETHOPRIM/SULFAMETHOXAZOLE (25 total), please visit the HSDB record page.
Trimethoprim-sulfamethoxazole should not be used to treat streptococcal pharyngitis, since it does not eradicate the microorganism.
Gilman, A.G., T.W. Rall, A.S. Nies and P. Taylor (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 8th ed. New York, NY. Pergamon Press, 1990., p. 1056
Since serious reactions such as the Stevens-Johnson syndrome have occurred in some individuals, therapy should be discontinued at the first appearance of skin rash or other adverse effects.
Hussar, D.A. (ed.). Modell's Drugs in Current Use and New Drugs. 38th ed. New York, NY: Springer Publishing Co., 1992., p. 165
May increase the action of warfarin and phenytoin.
Hussar, D.A. (ed.). Modell's Drugs in Current Use and New Drugs. 38th ed. New York, NY: Springer Publishing Co., 1992., p. 165
Should not be used in pregnancy at term or during the nursing period.
Hussar, D.A. (ed.). Modell's Drugs in Current Use and New Drugs. 38th ed. New York, NY: Springer Publishing Co., 1992., p. 165
For more Drug Warnings (Complete) data for TRIMETHOPRIM/SULFAMETHOXAZOLE (13 total), please visit the HSDB record page.
Anti-Infective Agents, Urinary
Substances capable of killing agents causing urinary tract infections or of preventing them from spreading. (See all compounds classified as Anti-Infective Agents, Urinary.)
Anti-Bacterial Agents
Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)
Antimalarials
Agents used in the treatment of malaria. They are usually classified on the basis of their action against plasmodia at different stages in their life cycle in the human. (From AMA, Drug Evaluations Annual, 1992, p1585) (See all compounds classified as Antimalarials.)
J - Antiinfectives for systemic use
J01 - Antibacterials for systemic use
J01E - Sulfonamides and trimethoprim
J01EE - Combinations of sulfonamides and trimethoprim, incl. derivatives
J01EE01 - Sulfamethoxazole and trimethoprim
Co-trimoxazole is widely distributed into body tissues and fluids, including sputum, aqueous humor, middle ear fluid, prostatic fluid, vaginal fluid, bile, and cerebrospinal fluid; trimethoprim also distributes into bronchial secretions. Trimethoprim has a larger volume of distribution than does sulfamethoxazole. In adults, apparent volume of distribution of 100-120 and 12-18 l have been reported for trimethoprim and sulfamethoxazole, respectively. In patients with uninflamed meninges, trimethoprim and sulfamethoxazole concentrations in cerebrospinal fluid are about 50 and 40%, respectively, of concurrent serum concentrations of the drugs. Trimethoprim and sulfamethoxazole concentrations in middle ear fluid are approximately 75 and 20%, respectively, and in prostatic fluid are approximately 200 and 35%, respectively, of concurrent serum concentrations of the drugs.
McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 92. Bethesda, MD: American Society of Hospital Pharmacists, Inc., 1992 (Plus Supplements 1992)., p. 461
After a single oral dose of the combined preparation, trimethoprim is absorbed more rapidly than sulfamethoxazole. The concurrent administration of the drugs appears to slow the absorption of sulfamethoxazole. Peak blood concentrations of trimethoprim ususally occur by 2 hours in most patients, while peak concentrations of sulfamethoxazole occur by 4 hours after a single oral dose.
Gilman, A.G., T.W. Rall, A.S. Nies and P. Taylor (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 8th ed. New York, NY. Pergamon Press, 1990., p. 1055
Trimethoprim is rapidly distributed and concentrated in tissues, and about 40% is bound to plasma protein in the presence of sulfamethoxazole. The volume of distribution of trimethoprim is almost nine times that of sulfamethoxazole. The drug readily enters cerebrospinal fluid and sputum. High concentrations of each component of the mixture are also found in bile.
Gilman, A.G., T.W. Rall, A.S. Nies and P. Taylor (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 8th ed. New York, NY. Pergamon Press, 1990., p. 1055
The pharmacokinetics of trimethoprim-sulfamethoxazole were studied in 12 healthy adult subjects receiving trimethoprim at 20 mg/kg of body weight per day and sulfamethoxazole at 100 mg/kg/day, which is the conventional dose for treating Pneumocystis carinii pneumonia. Daily doses were evenly divided and orally administered every 6 h for 3 days. Trimethoprim, sulfamethoxazole, and N4-acetylsulfamethoxazole concn in serum and urine were measured by HPLC. Five subjects withdrew from the study because of intolerable GI and CNS toxicities. In the seven subjects that completed the study, the mean maximum serum drug concn after the last dose were 13.6 + or - 2.0, 372 + or - 64, and 50.1 + or - 10.9 ug/ml for trimethoprim, sulfamethoxazole, and N4-acetylsulfamethoxazole, respectively. The mean half-lives were 13.6 + or - 3.5, 14.0 + or - 2.3, and 18.6 + or - 4.3 hr, respectively. Changes in absolute neutrophil count were significantly correlated with the minimum concn of trimethoprim and sulfamethoxazole in serum and trimethoprim area under the concn-time curve (for all three parameters, r2 = 0.6 and p < 0.05). These findings add to the evidence that serum drug concn in adults following the conventional dose of trimethoprim-sulfamethoxazole for Pneumocystis carinii pneumonia are excessive and contribute to certain adverse reactions.
Stevens RC et al; Antimicrob Agents Chemother 35 (9): 1991 1884-90 (1990)
This article reviews the pharmacokinetics, clinical use, and adverse effects of trimethoprim/sulfamethoxazole in renally impaired patients. Renal dysfunction changes the pharmacokinetics of both component drugs. Trimethoprim and sulfamethoxazole disposition are not significantly altered until creatinine clearance is less than 30 ml/min, when sulfamethoxazole metabolites and trimethoprim accumulate and may lead to toxicity. Renal dysfunction, however, does not preclude the use of trimethoprim/sulfamethoxazole to treat susceptible infections, even when creatinine clearance is less than 15 ml/min. Adverse effects may occur more frequently in renally impaired patients but are not clearly related to increased serum concentrations of either drug. Guidelines for appropriate dosing and monitoring of trimethoprim/sulfamethoxazole therapy in these patients are presented.
PMID:2678767 Paap CM, Nahata MC; DICP 23 (9): 646-54 (1989)
Co-trimoxazole is metabolized in the liver. Trimethoprim is metabolized to oxide and hydroxylated metabolites and sulfamethoxazole is principally N-acetylated and also conjugated with glucuronic acid. Both drugs are rapidly excreted in urine via glomerular filtration and tubular secretion. In adults with normal renal function, approximately 50-60% of a trimethoprim and 45-70% of a sulfamethoxazole oral dose are excreted in urine within 24 hours. Approximately 80% of the amount of trimethoprim and 20% of the amount of sulfamethoxazole recovered in urine are unchanged drug. In adults with normal renal function, urinary concentrations of active trimethoprim are approximately equal to those of active sulfamethoxazole. Urinary concentrations of both active drugs are decreased in patients with impaired renal function.
McEvoy, G.K. (ed.). American Hospital Formulary Service - Drug Information 92. Bethesda, MD: American Society of Hospital Pharmacists, Inc., 1992 (Plus Supplements 1992)., p. 461
The half-lives of trimethoprim and sulfamethoxazole are approximately 11 and 10 hours, respectively.
Gilman, A.G., T.W. Rall, A.S. Nies and P. Taylor (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 8th ed. New York, NY. Pergamon Press, 1990., p. 1055
Trimethoprim/sulfamethoxazole ... inhibits sequential steps in the synthesis of tetrahydrofolic acid, an essential metabolic cofactor in the bacterial synthesis of purines, thymidine, glycine, and methionine. Sulfonamides, including sulfamethoxazole, are structural analogues of para-aminobenzoic acid and block the synthesis of dihydropteroic acid, the immediate precursor of dihydrofolic acid, from para-aminobenzoic acid and peridine. Trimethoprim subsequently acts to inhibit the reduction of dihydrofolic acid to the metabolically active tetrahydrofolic acid by the enzyme, dihydrofolate reductase. The most important consequence of this sequential enzymatic inhibition appears to be the interruption of thymidine synthesis.
American Medical Association. AMA Drug Evaluations Annual 1991. Chicago, IL: American Medical Association, 1991., p. 1343
The synergistic interaction between sulfonamide and trimethoprim is thus predictable from their respective mechanisms. There is an optimal ratio of the concentrations of the two agents for synergism, and this is equal to the ratio of the minimal inhibitory concentrations of the drugs acting independently. While this ratio varies for different bacteria, the most effective ratio for the greatest number of microorganisms is 20 parts of sulfamethoxazole to one part of trimethoprim. The combination is formulated to achieve a sulfamethoxazole concentration in vivo 20 times greater than that of trimethoprim. ... The pharmacokinetic properties of the sulfonamide chosen to be in combination with trimethoprim are important, since relative constancy of the concentrations of the two compounds in the body is desired.
Gilman, A.G., T.W. Rall, A.S. Nies and P. Taylor (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 8th ed. New York, NY. Pergamon Press, 1990., p. 1054
Trimethoprim/sulfamethoxazole is active in vitro against a variety of gram-negative and gram-postive bacteria. Among aerobic gram-negative enteric bacteria, Escherichia coli, Proteus mirabilis, Salmonella (including Salmonella typhi), Shigella, and Citrobacter are very susceptible. Indole-positive Proteus, Serratia marcescens, Klebsiella pneumoniae, Enterobacter, Providencia stuartii are moderately susceptible.
American Medical Association. AMA Drug Evaluations Annual 1991. Chicago, IL: American Medical Association, 1991., p. 1344
An immunoassay was developed for the detection of sulfamethoxazole reactive IgE antibodies in the sera of patients who experienced life threatening anaphylactic reactions following the ingestion of co-trimoxazole (trimethoprim and sulfamethoxazole). Patients who had significant levels of sulfamethoxazole reactive IgE antibodies in their sera did not have IgE antibodies that reacted with trimethoprim-Sepharose. Inhibition experiments with a number of sulfonamides to determine the fine structural specificities of the sulfamethoxazole reactive IgE antibodies in three patients revealed that sulfamethoxazole and, depending on the serum, sulfamerazine and sulfamethizole, were the most potent inhibitors of IgE binding, whereas the parent sulfonamide, sulfanilamide, was a very poor inhibitor. From a detailed examination of structure-activity relationships, we concluded that the 5-methyl-3-isoxazolyl group on the sulfamethoxazole molecule was the allergenic determinant for all three patients with the 5-methyl group being particularly important for IgE antibody recognition. The assays for the detection of IgE antibodies to sulfamethoxazole and trimethoprim should prove useful for the diagnosis of immediate hypersensitivity to co-trimoxazole and perhaps for monitoring drug therapy in AIDS patients where a high incidence of adverse reactions to co-trimoxazole has been reported.
PMID:3237218 Harle DG et al; Mol Immunol 25 (12): 1347-54 (1988)
Market Place
